$BIIB up a monster 30% today. I was curious why, and it turned out their blockbuster Alzheimer's drug, aducanumab, which they discontinued studying in March, may actually work. Stock tanked 30%+ then. Now it's back. Very odd situation.https://www.statnews.com/2019/10/22/biogen-to-submit-aducanumab/ …
Very suspicious. It's basically a symptomatic relief drug like aricept right? Unless what we call Alzheimer's is more than one disease, drugs that work on big N work on small N too.
-
-
I don't think it's supposed to be merely symptomatic. It targets beta amyloid so it may plausibly slow down Alzheimer's. If it works, it's huge.
-
Bizarre. I am very skeptical.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.